Neurosurgery of KUH NeuroCenter, Kuopio, Kuopio University Hospital, and Faculty of Health Sciences, School of Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Neurosurgery. 2019 May 1;84(5):1011-1018. doi: 10.1093/neuros/nyy194.
BACKGROUND: Failed back surgery syndrome (FBSS) is a challenging condition that lacks a curative treatment. In selected patients, spinal cord stimulation (SCS) has provided a satisfactory outcome. OBJECTIVE: To evaluate the long-term outcome of SCS in FBSS, as measured by (1) the explantation rate, (2) complications, and (3) patient satisfaction with the global perceived effect (GPE). METHODS: We studied 224 consecutive FBSS patients who underwent an SCS trial with surgically implanted leads at our hospital between January 1996 and December 2014. The patients' satisfaction with the GPE of treatment was measured through a postal questionnaire at the end of follow-up. RESULTS: Based on a 1-wk trial, permanent SCS was implanted in 175 (78%) patients. Out of these patients, 153 (87%) reported satisfactory outcomes after 2 mo. During the mean follow-up of 6 yr, 34 (19%) of SCS devices were permanently explanted due to inadequate pain relief, and 11 (6%) were explanted for other reasons.Electrode revision due to inadequate pain relief was done for 22 patients. In total, 26 complications were reported due to: 7 deep infections, 11 hardware malfunctions, 1 subcutaneous hematoma, 4 instances of discomfort due to the pulse generator, and 3 electrode migrations.One hundred thirty patients (74%) continued with SCS until the end of follow-up. Of them, 61 (47%) returned the questionnaire, and 42 (69%) reported substantially improved or better GPE. CONCLUSION: SCS can provide a good outcome in the treatment of FBSS. Patient selection could be further improved by developing novel predictive biomarkers.
背景:失败的腰椎手术后综合征(FBSS)是一种具有挑战性的病症,缺乏有效的治疗方法。在一些特定患者中,脊髓刺激(SCS)已经取得了满意的效果。 目的:通过(1)取出率、(2)并发症和(3)患者对总体感知效果(GPE)的满意度来评估 SCS 在 FBSS 中的长期效果。 方法:我们研究了 224 例连续的 FBSS 患者,他们在 1996 年 1 月至 2014 年 12 月期间在我院接受了 SCS 试验,手术植入了导联。通过邮寄问卷的方式在随访结束时评估患者对治疗的 GPE 满意度。 结果:根据 1 周的试验,175 例(78%)患者永久性植入了 SCS。在这些患者中,有 153 例(87%)在 2 个月后报告了满意的结果。在平均 6 年的随访中,由于疼痛缓解不足,34 例(19%)的 SCS 设备永久取出,11 例(6%)因其他原因取出。由于疼痛缓解不足,对 22 例患者进行了电极修订。共报告了 26 例并发症,包括:7 例深部感染、11 例硬件故障、1 例皮下血肿、4 例因脉冲发生器引起的不适和 3 例电极移位。共有 130 例(74%)患者一直使用 SCS 直到随访结束。其中,61 例(47%)患者返回了问卷,42 例(69%)报告 GPE 明显改善或更好。 结论:SCS 可有效治疗 FBSS。通过开发新的预测生物标志物,可以进一步改善患者选择。
Spine (Phila Pa 1976). 2014-5-20
Adv Exp Med Biol. 2024
Stereotact Funct Neurosurg. 2025
J Health Econ Outcomes Res. 2024-5-28
J Orthop Translat. 2023-9-30
Oper Neurosurg (Hagerstown). 2023-8-1